BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 3.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,630,942 shares of the company’s stock after selling 50,906 shares during the period. Johnson & Johnson makes up about 1.7% of BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s investment portfolio, making the stock its 3rd biggest position. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned approximately 0.06% of Johnson & Johnson worth $215,757,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. State Street Corp increased its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Johnson & Johnson by 4.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 11,623,639 shares of the company’s stock worth $1,537,692,000 after acquiring an additional 473,300 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of Johnson & Johnson by 3.7% during the second quarter. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock worth $1,521,258,000 after acquiring an additional 405,517 shares in the last quarter. Clearbridge Investments LLC increased its position in shares of Johnson & Johnson by 3.4% during the first quarter. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock worth $1,188,684,000 after acquiring an additional 310,831 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Johnson & Johnson by 6.3% during the second quarter. Bank of Montreal Can now owns 7,266,065 shares of the company’s stock worth $961,226,000 after acquiring an additional 428,310 shares in the last quarter. Institutional investors and hedge funds own 65.91% of the company’s stock.

JNJ has been the subject of several research reports. Cowen reissued an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reissued a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group increased their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $144.59.

Johnson & Johnson (NYSE JNJ) traded down $0.21 during trading on Thursday, reaching $139.81. 5,851,400 shares of the company were exchanged, compared to its average volume of 5,859,932. The company has a market capitalization of $376,166.53, a P/E ratio of 19.61, a P/E/G ratio of 2.85 and a beta of 0.82. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.68 earnings per share. analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/30/johnson-johnson-jnj-shares-sold-by-british-columbia-investment-management-corp.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.